PLN 101325
Alternative Names: PLN-101325Latest Information Update: 10 May 2024
At a glance
- Originator Pliant Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Integrin alpha7beta1 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Muscular dystrophies
Most Recent Events
- 06 May 2024 Pliant Therapeutics plans a phase I trial for Muscular dystrophy in Australia
- 09 May 2023 Pliant Therapeutics announces intention to submit IND application for Duchenne muscular dystrophy in the first quarter of 2024
- 09 May 2023 Pliant Therapeutics plans a clinical trial for Duchenne muscular dystrophy in 2023